Eliem Therapeutics Income from Discontinued Operations 2021-2024 | CLYM
Eliem Therapeutics income from discontinued operations from 2021 to 2024. Income from discontinued operations can be defined as income or loss from the complete discontinuation of a segment or business, net of associated taxes and fees.
Eliem Therapeutics Annual Income from Discontinued Operations (Millions of US $) |
2023 |
$ |
2022 |
$ |
2021 |
$ |
2020 |
$ |
Eliem Therapeutics Quarterly Income from Discontinued Operations (Millions of US $) |
2024-06-30 |
|
2024-03-31 |
|
2023-12-31 |
|
2023-09-30 |
|
2023-06-30 |
|
2023-03-31 |
|
2022-12-31 |
|
2022-09-30 |
|
2022-06-30 |
|
2022-03-31 |
|
2021-12-31 |
|
2021-09-30 |
|
2021-06-30 |
|
2021-03-31 |
|
2020-12-31 |
|
2020-09-30 |
|
2020-06-30 |
|
Sector |
Industry |
Market Cap |
Revenue |
Medical |
MED-DRUGS |
$0.346B |
$0.000B |
Eliem Therapeutics Inc. is a clinical-stage biotechnology company. It focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Eliem Therapeutics Inc. is based in SEATTLE, United Kingdom.
|